HK1201569A1 - Prediction of likelihood of cancer recurrence - Google Patents

Prediction of likelihood of cancer recurrence

Info

Publication number
HK1201569A1
HK1201569A1 HK15102130.0A HK15102130A HK1201569A1 HK 1201569 A1 HK1201569 A1 HK 1201569A1 HK 15102130 A HK15102130 A HK 15102130A HK 1201569 A1 HK1201569 A1 HK 1201569A1
Authority
HK
Hong Kong
Prior art keywords
likelihood
prediction
cancer recurrence
recurrence
cancer
Prior art date
Application number
HK15102130.0A
Other languages
English (en)
Chinese (zh)
Inventor
Joffre Baker
John L Bryant
Soonmyung Paik
Steve Shak
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34519967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1201569(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Publication of HK1201569A1 publication Critical patent/HK1201569A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
HK15102130.0A 2003-06-24 2015-03-03 Prediction of likelihood of cancer recurrence HK1201569A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48233903P 2003-06-24 2003-06-24

Publications (1)

Publication Number Publication Date
HK1201569A1 true HK1201569A1 (en) 2015-09-04

Family

ID=34519967

Family Applications (2)

Application Number Title Priority Date Filing Date
HK17105303.2A HK1231521A1 (zh) 2003-06-24 2015-03-03 癌症復發的可能性預測
HK15102130.0A HK1201569A1 (en) 2003-06-24 2015-03-03 Prediction of likelihood of cancer recurrence

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK17105303.2A HK1231521A1 (zh) 2003-06-24 2015-03-03 癌症復發的可能性預測

Country Status (11)

Country Link
US (5) US7056674B2 (xx)
EP (4) EP2775000B1 (xx)
JP (1) JP4680898B2 (xx)
AU (2) AU2004283068B2 (xx)
CA (2) CA3061769C (xx)
DK (4) DK2775000T3 (xx)
ES (4) ES2787475T3 (xx)
HK (2) HK1231521A1 (xx)
HU (1) HUE050365T2 (xx)
PL (1) PL3470535T3 (xx)
WO (1) WO2005039382A2 (xx)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
EP2258872B1 (en) * 2002-03-13 2013-08-14 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
JP2006515742A (ja) * 2002-08-27 2006-06-08 ブリストル−マイヤーズ　スクイブ　カンパニー 乳癌細胞でのプロテインチロシンキナーゼおよび／またはプロテインチロシンキナーゼ経路と相互作用および／またはモデュレートする化合物の活性を予測するためのポリヌクレオチドの同定
US7537891B2 (en) * 2002-08-27 2009-05-26 Bristol-Myers Squibb Company Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cells
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
US10533998B2 (en) 2008-07-18 2020-01-14 Bio-Rad Laboratories, Inc. Enzyme quantification
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
CA3061769C (en) 2003-06-24 2021-10-26 Genomic Health, Inc. Methods of predicting the likelihood of long-term survival of a human patient with node-negative, estrogen receptor (er) positive, invasive ductal breast cancer without the recurrence of breast cancer
US9856533B2 (en) 2003-09-19 2018-01-02 Biotheranostics, Inc. Predicting breast cancer treatment outcome
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
EP1737980A2 (en) 2004-04-09 2007-01-03 Fondazione IRCCS Istituto Nazionale dei Tumori Gene expression markers for predicting response to chemotherapy
CA2575557A1 (en) * 2004-07-30 2006-02-09 Rosetta Inpharmatics Llc Prognosis of breast cancer patients
WO2006016525A2 (en) * 2004-08-10 2006-02-16 Oncotherapy Science, Inc. Genes and polypeptides relating to breast cancers
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
NZ554895A (en) * 2004-11-03 2009-06-26 Almac Diagnostics Ltd Transcriptome microarray technology and methods of using the same
JP5020088B2 (ja) * 2004-11-05 2012-09-05 ジェノミック ヘルス， インコーポレイテッド 遺伝子発現マーカーを使用する、化学療法に対する反応の予測
ZA200704796B (en) * 2004-12-07 2008-11-26 Genentech Inc Selecting patients for therapy with a HER inhibitor
US7595380B2 (en) * 2005-04-27 2009-09-29 Tripath Imaging, Inc. Monoclonal antibodies and methods for their use in the detection of cervical disease
US20080275652A1 (en) * 2005-05-13 2008-11-06 Universite Libre De Bruxelles Gene-based algorithmic cancer prognosis
EP1750131B1 (en) * 2005-08-01 2008-07-09 Sysmex Corporation Method for judging feature of malignant tumor
US20090215054A1 (en) * 2005-12-13 2009-08-27 Carter Scott L Prognosis indicators for solid human tumors
WO2007081386A2 (en) 2006-01-11 2007-07-19 Raindance Technologies, Inc. Microfluidic devices and methods of use
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
US20080014589A1 (en) 2006-05-11 2008-01-17 Link Darren R Microfluidic devices and methods of use thereof
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
IL282783B2 (en) 2006-05-18 2023-09-01 Caris Mpi Inc A system and method for determining a personalized medical intervention for a disease stage
EP2077912B1 (en) 2006-08-07 2019-03-27 The President and Fellows of Harvard College Fluorocarbon emulsion stabilizing surfactants
US7615349B2 (en) * 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
EP2081950B1 (en) * 2006-09-21 2013-03-20 Nuclea Biomarkers LLC Expression profiles associated with irinotecan treatment
SG142186A1 (en) * 2006-10-20 2008-05-28 Agency Science Tech & Res Breast tumour grading
US8772046B2 (en) 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
US8030060B2 (en) * 2007-03-22 2011-10-04 West Virginia University Gene signature for diagnosis and prognosis of breast cancer and ovarian cancer
US20090062144A1 (en) * 2007-04-03 2009-03-05 Nancy Lan Guo Gene signature for prognosis and diagnosis of lung cancer
US8592221B2 (en) 2007-04-19 2013-11-26 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
JP2008278798A (ja) * 2007-05-10 2008-11-20 Tokyo Medical & Dental Univ 膀胱癌の検出方法
AU2008289148A1 (en) * 2007-08-16 2009-02-26 Aventis Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
CN102395682B (zh) * 2007-09-06 2015-09-30 生物治疗诊断股份有限公司 肿瘤分级和癌症预后
WO2009048901A1 (en) * 2007-10-09 2009-04-16 University Of Washington Quantitative/semi-quantitative measurement of epor on cancer cells
WO2009052286A1 (en) * 2007-10-16 2009-04-23 Ventana Medical Systems, Inc. Grading, staging, and prognosing cancer using osteopontin-c
WO2009131365A2 (ko) * 2008-04-21 2009-10-29 한국생명공학연구원 위암 진단 마커로서의 ｃst1, ｄcc1, ifitm1 또는 ｍelk
KR100980004B1 (ko) 2008-04-21 2010-09-03 한국생명공학연구원 위암 진단 마커로서의 엠이엘케이
DK2294215T3 (da) 2008-05-12 2013-04-22 Genomic Health Inc Tests til forudsigelse af cancerpatienters respons på forskellige kemoterapeutiske behandlingsmuligheder
WO2010009365A1 (en) 2008-07-18 2010-01-21 Raindance Technologies, Inc. Droplet libraries
TWI466680B (zh) 2008-08-01 2015-01-01 Oncotherapy Science Inc Ｍｅｌｋ抗原決定位胜肽及含此胜肽的疫苗
US10359425B2 (en) * 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US20100221752A2 (en) * 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
US20110295782A1 (en) 2008-10-15 2011-12-01 Alexander Stojadinovic Clinical Decision Model
WO2010056337A2 (en) 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
CA2749103A1 (en) * 2009-01-07 2010-07-15 Steve Stone Cancer biomarkers
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
US8597885B2 (en) * 2009-01-28 2013-12-03 University Of Notre Dame Accelerated progression relapse test
US8528589B2 (en) 2009-03-23 2013-09-10 Raindance Technologies, Inc. Manipulation of microfluidic droplets
US20120309640A1 (en) * 2009-10-08 2012-12-06 Torti Frank M Diagnostic and Prognostic Markers for Cancer
EP2486409A1 (en) 2009-10-09 2012-08-15 Universite De Strasbourg Labelled silica-based nanomaterial with enhanced properties and uses thereof
DE102010043541B4 (de) 2009-12-16 2012-01-26 Technische Universität Dresden Verfahren und Mittel zur Vorhersage der Überlebensdauer beim Pankreaskarzinom durch Analyse von Biomarkern
US10837883B2 (en) 2009-12-23 2020-11-17 Bio-Rad Laboratories, Inc. Microfluidic systems and methods for reducing the exchange of molecules between droplets
NZ600268A (en) 2010-01-11 2014-08-29 Genomic Health Inc Method to use gene expression to determine likelihood of clinical outcome of renal cancer
TWI485245B (zh) 2010-01-25 2015-05-21 Oncotherapy Science Inc 經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
WO2011100604A2 (en) 2010-02-12 2011-08-18 Raindance Technologies, Inc. Digital analyte analysis
JP5808349B2 (ja) 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー セラノーシスのためのバイオマーカー
BR112012025593A2 (pt) 2010-04-06 2019-06-25 Caris Life Sciences Luxembourg Holdings biomarcadores em circulação para doença
CA2804391A1 (en) 2010-07-07 2012-01-12 Myriad Genetics, Inc. Gene signatures for cancer prognosis
SG186953A1 (en) 2010-07-09 2013-02-28 Somalogic Inc Lung cancer biomarkers and uses thereof
EP2913405B1 (en) 2010-07-27 2016-11-09 Genomic Health, Inc. Method for using gene expression to determine prognosis of prostate cancer
CN106198980B (zh) 2010-08-13 2018-09-07 私募蛋白质体公司 胰腺癌生物标记及其用途
EP2611941A4 (en) 2010-08-30 2014-01-22 Myriad Genetics Inc GENESIS OF CANCER DIAGNOSIS AND PROGNOSIS
EP3447155A1 (en) 2010-09-30 2019-02-27 Raindance Technologies, Inc. Sandwich assays in droplets
EP2648762B1 (en) 2010-12-09 2018-02-21 Biotheranostics, Inc. Post-treatment breast cancer prognosis
WO2012109600A2 (en) 2011-02-11 2012-08-16 Raindance Technologies, Inc. Methods for forming mixed droplets
WO2012112804A1 (en) 2011-02-18 2012-08-23 Raindance Technoligies, Inc. Compositions and methods for molecular labeling
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
AU2012272662A1 (en) * 2011-06-22 2014-01-16 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of cancer
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
WO2013023132A1 (en) 2011-08-10 2013-02-14 Wake Forest University Health Sciences Diagnostic and prognostic markers for cancer
KR20140057361A (ko) * 2011-08-31 2014-05-12 온코사이트 코포레이션 암의 치료 및 진단을 위한 방법 및 조성물
WO2013120089A1 (en) 2012-02-10 2013-08-15 Raindance Technologies, Inc. Molecular diagnostic screening assay
WO2013165748A1 (en) 2012-04-30 2013-11-07 Raindance Technologies, Inc Digital analyte analysis
CN104704128A (zh) * 2012-05-22 2015-06-10 纳米线科技公司 预测乳腺癌结果的nano46基因和方法
EP4190918A1 (en) 2012-11-16 2023-06-07 Myriad Genetics, Inc. Gene signatures for cancer prognosis
CA2896899A1 (en) 2013-01-18 2014-07-24 Ellis KLINE Selective glycosidase regimen for immune programming and treatment of cancer
WO2014124454A1 (en) 2013-02-11 2014-08-14 Katerina Gurova Use of facilitates chromatin transcription complex (fact) in cancer
EP2986762B1 (en) 2013-04-19 2019-11-06 Bio-Rad Laboratories, Inc. Digital analyte analysis
DK3004392T3 (da) 2013-05-30 2020-10-26 Genomic Health Inc Genekspressionsprofilalgoritme til beregning af en recidivscore for en patient med nyrecancer
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
EP3090063B1 (en) 2013-12-31 2019-11-06 Bio-Rad Laboratories, Inc. Method for detection of latent retrovirus
EP3623482A1 (en) 2014-05-13 2020-03-18 Myriad Genetics, Inc. Gene signatures for cancer prognosis
NZ730124A (en) 2014-09-19 2023-05-26 Univ College Dublin Nat Univ Ireland Dublin A method of predicting risk of recurrence of cancer
CA2965217A1 (en) 2014-10-24 2016-04-28 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
AU2015334842B2 (en) 2014-10-24 2022-02-17 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
ES2833543T3 (es) 2014-10-24 2021-06-15 Koninklijke Philips Nv Evaluación de la actividad de la ruta de señalización celular de TGF usando modelos matemáticos de la expresión de genes diana
CN108138237B (zh) 2015-08-14 2022-04-05 皇家飞利浦有限公司 使用靶基因表达的数学建模评估NFkB细胞信号传导途径活性
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
EP3374526A4 (en) 2015-11-13 2019-09-11 Biotheranostics, Inc. INTEGRATION OF TUMOR CHARACTERISTICS WITH A BREAST CANINE INDEX
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
EP3461915A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3502279A1 (en) 2017-12-20 2019-06-26 Koninklijke Philips N.V. Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1252046A (en) 1982-11-04 1989-04-04 Martin J. Cline Methods for oncogenic detection
USRE35491E (en) 1982-11-04 1997-04-08 The Regents Of The University Of California Methods and compositions for detecting human tumors
US4699877A (en) 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
US7838216B1 (en) 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5015568A (en) 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5202429A (en) 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5831066A (en) 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5858678A (en) 1994-08-02 1999-01-12 St. Louis University Apoptosis-regulating proteins
US5830753A (en) 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
DE69635740T2 (de) 1995-12-18 2006-09-14 Sugen, Inc., South San Francisco Diagnose und behandlung von mit aur-1 und/oder aur-2 assoziierten erkrankungen
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US5670325A (en) 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
US5962313A (en) 1996-01-18 1999-10-05 Avigen, Inc. Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
US5741650A (en) 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US5821082A (en) 1996-05-23 1998-10-13 St. Louis University Health Sciences Center Anti-proliferation domain of a human Bcl-2 and DNA encoding the same
US6143529A (en) 1996-08-14 2000-11-07 Exact Laboratories, Inc. Methods for improving sensitivity and specificity of screening assays
US6100029A (en) 1996-08-14 2000-08-08 Exact Laboratories, Inc. Methods for the detection of chromosomal aberrations
US5952178A (en) 1996-08-14 1999-09-14 Exact Laboratories Methods for disease diagnosis from stool samples
US6146828A (en) 1996-08-14 2000-11-14 Exact Laboratories, Inc. Methods for detecting differences in RNA expression levels and uses therefor
US6020137A (en) 1996-08-14 2000-02-01 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6203993B1 (en) 1996-08-14 2001-03-20 Exact Science Corp. Methods for the detection of nucleic acids
US5928870A (en) 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US5861278A (en) 1996-11-01 1999-01-19 Genetics Institute, Inc. HNF3δ compositions
KR100645448B1 (ko) 1996-11-20 2006-11-13 예일 유니버시티 세포 아폽토시스를 저해하는 설바이빈 단백질 및 이를 조절하는 방법
US5846723A (en) * 1996-12-20 1998-12-08 Geron Corporation Methods for detecting the RNA component of telomerase
US5830665A (en) 1997-03-03 1998-11-03 Exact Laboratories, Inc. Contiguous genomic sequence scanning
US6033893A (en) 1997-06-26 2000-03-07 Incyte Pharmaceuticals, Inc. Human cathepsin
WO1999002714A1 (en) 1997-07-07 1999-01-21 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
AUPO938897A0 (en) * 1997-09-23 1997-10-16 Garvan Institute Of Medical Research A potential effector for the grb7 family of signalling proteins
US6358682B1 (en) * 1998-01-26 2002-03-19 Ventana Medical Systems, Inc. Method and kit for the prognostication of breast cancer
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
AU766544B2 (en) 1998-06-06 2003-10-16 Genostic Pharma Limited Probes used for genetic profiling
US6696558B2 (en) 1998-09-09 2004-02-24 The Burnham Institute Bag proteins and nucleic acid molecules encoding them
AU3246200A (en) 1999-02-25 2000-09-14 Boris Bilynsky Nucleic acid molecules associated with melanoma and thyroid tumors
US20020039764A1 (en) 1999-03-12 2002-04-04 Rosen Craig A. Nucleic, acids, proteins, and antibodies
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6692916B2 (en) 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
WO2001004343A2 (en) * 1999-07-09 2001-01-18 The Burnham Institute A method for determining the prognosis of cancer patients by measuring levels of bag expression
US6326148B1 (en) 1999-07-12 2001-12-04 The Regents Of The University Of California Detection of copy number changes in colon cancer
US6710170B2 (en) 1999-09-10 2004-03-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6271002B1 (en) 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
EP1218394A4 (en) 1999-10-06 2004-04-14 Univ California DIFFERENTIAL EXPRESSION GENES ASSOCIATED WITH OVER-EXPRESSION OF HER-2 / NEU
EP2228446A1 (en) 1999-12-01 2010-09-15 Genentech, Inc. Secreted and transmembrane polypeptieds and nucleic acids encoding the same
US6750013B2 (en) 1999-12-02 2004-06-15 Protein Design Labs, Inc. Methods for detection and diagnosing of breast cancer
US6248535B1 (en) * 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
WO2001051661A2 (en) 2000-01-13 2001-07-19 Amsterdam Support Diagnostics B.V. A universal nucleic acid amplification system for nucleic acids in a sample
US6322986B1 (en) 2000-01-18 2001-11-27 Albany Medical College Method for colorectal cancer prognosis and treatment selection
EP1257664A4 (en) 2000-01-28 2006-04-05 Althea Technologies Inc METHOD FOR THE ANALYSIS OF GENE EXPRESSION
CA2395398A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU4592601A (en) 2000-03-21 2001-10-03 Millennium Predictive Medicine Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer
AU2001251086A1 (en) 2000-03-31 2001-10-15 Sir Mortimer B. Davis Jewish General Hospital Microchip arrays of regulatory genes
WO2002000677A1 (en) 2000-06-07 2002-01-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
WO2001098359A2 (en) * 2000-06-21 2001-12-27 Wyeth Cyr61 as a target for treatment and diagnosis of breast cancer
ATE445164T1 (de) * 2000-06-22 2009-10-15 Univ Paris Descartes Zusammensetzungen und methoden zum nachweis, behandeln oder vorhersagen der antwort von brust tumorzellen auf eine endocrin-therapie
WO2002008461A2 (en) 2000-07-21 2002-01-31 Global Genomics Ab A METHOD AND AN ALGORITHM FOR mRNA EXPRESSION ANALYSIS
AU2001278011A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-ecg1 protein and related reagents and methods of use thereof
US7118853B2 (en) 2000-07-26 2006-10-10 Applied Genomics, Inc. Methods of classifying, diagnosing, stratifying and treating cancer patients and their tumors
AU2001277202A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-ras/rerg protein and related reagents and methods of use thereof
WO2002010436A2 (en) * 2000-07-28 2002-02-07 The Brigham And Women's Hospital, Inc. Prognostic classification of breast cancer
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US20020156263A1 (en) * 2000-10-05 2002-10-24 Huei-Mei Chen Genes expressed in breast cancer
FR2815025B1 (fr) 2000-10-06 2003-08-29 Eurodim Sa Systeme de transfert d'un produit fluide, notamment du gaz naturel liquefie a temperature cryogenique, entre un navire de transport et une installation terrestre de traitement et de stockage de ce produit
WO2002036142A2 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
US6582919B2 (en) 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
US6602670B2 (en) 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
AU2002234799A1 (en) * 2000-12-08 2002-06-18 Ipsogen Gene expression profiling of primary breast carcinomas using arrays of candidate genes
AU2002255478A1 (en) 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US7776518B2 (en) 2001-01-12 2010-08-17 Yale University Detection of survivin in the biological fluids of cancer patients
WO2002057787A2 (en) 2001-01-12 2002-07-25 Yale University Detection of survivin in the biological fluids of cancer patients
MXPA03006617A (es) 2001-01-24 2004-12-02 Protein Design Labs Inc Metodos de diagnostico de cancer de pecho, composiciones y metodos de rastreo de moduladores de cancer de pecho.
US20070015148A1 (en) 2001-01-25 2007-01-18 Orr Michael S Gene expression profiles in breast tissue
CN1554025A (zh) 2001-03-12 2004-12-08 Īŵ���ɷ����޹�˾ 患病状态的细胞为基础的检测和鉴别
JP4222835B2 (ja) * 2001-03-14 2009-02-12 株式会社Ｄｎａチップ研究所 癌の予測方法
US20020194022A1 (en) * 2001-04-06 2002-12-19 Florence Comite System and method for delivering integrated health care
US7514209B2 (en) 2001-06-18 2009-04-07 Rosetta Inpharmatics Llc Diagnosis and prognosis of breast cancer patients
WO2003011897A1 (en) 2001-07-27 2003-02-13 The Regents Of The University Of California Modulation of heregulin and her3 interaction
WO2003029273A2 (en) 2001-09-28 2003-04-10 Whitehead Institute For Biomedical Research Classification of lung carcinomas using gene expression analysis
US6964850B2 (en) 2001-11-09 2005-11-15 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
EP1492871A2 (en) 2002-03-28 2005-01-05 QLT Inc. Cancer associated protein kinases and their uses
EP1365034A3 (en) 2002-05-21 2004-02-18 Bayer HealthCare AG Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
PT1597391E (pt) * 2003-02-20 2008-12-19 Genomic Health Inc Utilização de arn intrónico para medir a expressão genética
WO2004111603A2 (en) 2003-05-28 2004-12-23 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
CA3061769C (en) * 2003-06-24 2021-10-26 Genomic Health, Inc. Methods of predicting the likelihood of long-term survival of a human patient with node-negative, estrogen receptor (er) positive, invasive ductal breast cancer without the recurrence of breast cancer
WO2005008213A2 (en) * 2003-07-10 2005-01-27 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
EP1737980A2 (en) * 2004-04-09 2007-01-03 Fondazione IRCCS Istituto Nazionale dei Tumori Gene expression markers for predicting response to chemotherapy
DK1815014T3 (da) * 2004-11-05 2012-06-18 Genomic Health Inc Molekylære indikatorer for brystcancerprognose og forudsigelse af behandlingsrespons
JP5020088B2 (ja) * 2004-11-05 2012-09-05 ジェノミック ヘルス， インコーポレイテッド 遺伝子発現マーカーを使用する、化学療法に対する反応の予測
AU2006259583A1 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
AU2008289148A1 (en) 2007-08-16 2009-02-26 Aventis Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
DK2294215T3 (da) * 2008-05-12 2013-04-22 Genomic Health Inc Tests til forudsigelse af cancerpatienters respons på forskellige kemoterapeutiske behandlingsmuligheder

Also Published As

Publication number Publication date
HUE050365T2 (hu) 2022-09-28
EP3170906A1 (en) 2017-05-24
US20060286565A1 (en) 2006-12-21
US7056674B2 (en) 2006-06-06
CA2530738A1 (en) 2005-05-06
US20100267032A1 (en) 2010-10-21
CA3061769C (en) 2021-10-26
WO2005039382A2 (en) 2005-05-06
EP3470535B1 (en) 2020-04-01
EP3170906B1 (en) 2018-08-22
DK3170906T3 (en) 2018-11-05
HK1231521A1 (zh) 2017-12-22
US20200299781A1 (en) 2020-09-24
US20180051348A1 (en) 2018-02-22
CA3061769A1 (en) 2005-05-06
WO2005039382A3 (en) 2006-01-12
AU2010202424A1 (en) 2010-07-01
DK1641810T3 (da) 2014-08-04
EP1641810B1 (en) 2014-05-14
EP1641810B2 (en) 2017-04-19
EP2775000A1 (en) 2014-09-10
JP2007521005A (ja) 2007-08-02
US7723033B2 (en) 2010-05-25
EP1641810A4 (en) 2009-03-25
CA2530738C (en) 2020-01-21
ES2609234T3 (es) 2017-04-19
AU2010202424B2 (en) 2012-12-06
ES2488845T3 (es) 2014-08-29
EP3470535A1 (en) 2019-04-17
AU2004283068B2 (en) 2010-03-18
DK1641810T4 (en) 2017-07-03
ES2488845T5 (es) 2017-07-11
EP2775000B1 (en) 2016-11-09
DK2775000T3 (en) 2017-02-13
AU2004283068A1 (en) 2005-05-06
JP4680898B2 (ja) 2011-05-11
EP1641810A2 (en) 2006-04-05
US20050079518A1 (en) 2005-04-14
DK3470535T3 (da) 2020-06-29
PL3470535T3 (pl) 2020-08-24
US10619215B2 (en) 2020-04-14
ES2690168T3 (es) 2018-11-19
ES2787475T3 (es) 2020-10-16

Similar Documents

Publication Publication Date Title
HK1231521A1 (zh) 癌症復發的可能性預測
EP1697497A4 (en) LIVER CANCER BIOMARKERS
EP1667680A4 (en) COMBINED METHODS OF TREATING CANCER
AU2003294205A8 (en) Prostate cancer biomarkers
EP1613308A4 (en) CANCER TREATMENT METHODS
AU2003253860A8 (en) Expression profile of lung cancer
TWI317753B (en) Cmp of noble metals
GB0228900D0 (en) Cancer Immunotherapy
AU2003279101A8 (en) Methylation profile of cancer
EP1496923A4 (en) IMMUNOTHERAPY AGAINST CANCER
EP1625853A4 (en) APOPTOSIS INDUCER FOR CANCER CELL
EP1685423A4 (en) INDIVIDUAL RADIOBALISE OF REPERAGE
AU2003278211A8 (en) Methods for detection of genetic alterations associated with cancer
GB0226595D0 (en) Cancer therapy determination
GB0329416D0 (en) Treatment of cancer
EP1693069A4 (en) MEANS FOR THE TREATMENT OF SOLID TUMORS
AU2003903274A0 (en) Method of assessing cancer risk
GB0200110D0 (en) Cancer detection
EP1616190A4 (en) DIAGNOSIS OF CANCER AT AN ADVANCED STAGE
GB0328690D0 (en) Tumour suppressor protein
EP1595546A4 (en) REMEDIES AGAINST CANCER
GB0329820D0 (en) Anti cancer compounds
GB0410379D0 (en) Treatment of cancer
GB0423273D0 (en) Treatment of cancer
GB0218725D0 (en) Cancer related methods